Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...

BeiGene (NASDAQ:BGNE – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. Several ...

Moving to the Liver Disease portfolio on Slide 11 ... including our Phase 2 iMMagine 1 results for Anito-cel in fourth-line or later relapsed or refractory multiple myeloma. The ASH abstract shared ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Fibrolamellar hepatocellular carcinoma is a rare liver cancer that occurs in teenagers and adults ... Bruce Springsteen provided an update on his wife’s multiple myeloma. Bruce Springsteen recently ...

Operator Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in a moment. (Operator Instructions) I'll now hand the ...